Announcements

September is designated as “Thyroid Cancer Awareness Month”, with various global activities that highlight and increase awareness of thyroid cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of thyroid cancer, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Papillary Thyroid Cancer Prognosis: An Evolving Field”
by Salvatore Ulisse, Enke Baldini, Augusto Lauro, Daniele Pironi, Domenico Tripodi, Eleonora Lori, Iulia Catalina Ferent, Maria Ida Amabile, Antonio Catania, Filippo Maria Di Matteo et al.
Cancers 2021, 13(21), 5567; https://doi.org/10.3390/cancers13215567
Available online: https://www.mdpi.com/2072-6694/13/21/5567

“Fluorescence Image-Guided Surgery for Thyroid Cancer: Utility for Preventing Hypoparathyroidism”
by Marco Stefano Demarchi, Barbara Seeliger, Jean-Christophe Lifante, Pier Francesco Alesina and Frédéric Triponez
Cancers 2021, 13(15), 3792; https://doi.org/10.3390/cancers13153792
Available online: https://www.mdpi.com/2072-6694/13/15/3792

“Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer”
by Marotta Vincenzo, Maurizio Bifulco and Mario Vitale
Cancers 2021, 13(15), 3785; https://doi.org/10.3390/cancers13153785
Available online: https://www.mdpi.com/2072-6694/13/15/3785

“Deep Learning Fast Screening Approach on Cytological Whole Slides for Thyroid Cancer Diagnosis”
by Yi-Jia Lin, Tai-Kuang Chao, Muhammad-Adil Khalil, Yu-Ching Lee, Ding-Zhi Hong, Jia-Jhen Wu and Ching-Wei Wang
Cancers 2021, 13(15), 3891; https://doi.org/10.3390/cancers13153891
Available online: https://www.mdpi.com/2072-6694/13/15/3891

“Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?”
by Krzysztof Kaliszewski, Maksymilian Ludwig, Bartłomiej Ludwig, Agnieszka Mikuła, Maria Greniuk and Jerzy Rudnicki
Cancers 2022, 14(15), 3643; https://doi.org/10.3390/cancers14153643
Available online: https://www.mdpi.com/2072-6694/14/15/3643

“Translational Utility of Liquid Biopsies in Thyroid Cancer Management”
by Ayanthi A.Wijewardene, Marthe Chehade, Matti L. Gild, Roderick J. Clifton-Bligh and Martyn Bullock
Cancers 2021, 13(14), 3443; https://doi.org/10.3390/cancers13143443
Available online: https://www.mdpi.com/2072-6694/13/14/3443

“Piperlongumine, a Potent Anticancer Phytotherapeutic, Induces Cell Cycle Arrest and Apoptosis In Vitro and In Vivo through the ROS/Akt Pathway in Human Thyroid Cancer Cells”
by Fang-Ping Kung, Yun-Ping Lim, Wen-Ying Chao, Yi-Sheng Zhang, Hui-I Yu, Tsai-Sung Tai, Chieh-Hsiang Lu, Shu-Hsin Chen, Yi-Zhen Li, Pei-Wen Zhao et al.
Cancers 2021, 13(17); 4266. https://doi.org/10.3390/cancers13174266
Available online: https://www.mdpi.com/2072-6694/13/17/4266

“Molecular Genetics of Follicular-Derived Thyroid Cancer”
by Elisabetta Macerola, Anello Marcello Poma, Paola Vignali, Alessio Basolo, Clara Ugolini, Liborio Torregrossa, Ferruccio Santini and Fulvio Basolo
Cancers 2021, 13(5); 1139; https://doi.org/10.3390/cancers13051139
Available online: https://www.mdpi.com/2072-6694/13/5/1139

“Oxidative Stress Correlates with More Aggressive Features in Thyroid Cancer“
by Marina Muzza, Gabriele Pogliaghi, Carla Colombo, Erika Carbone, Valentina Cirello, Sonia Palazzo, Francesco Frattini, Davide Gentilini, Giacomo Gazzano, Luca Persani et al.
Cancers 2022, 14(23), 5857; https://doi.org/10.3390/cancers14235857
Available online: https://www.mdpi.com/2072-6694/14/23/5857

“Current Management of Bone Metastases from Differentiated Thyroid Cancer”
by Satoshi Kato, Satoru Demura, Kazuya Shinmura, Noriaki Yokogawa, Takaki Shimizu and Hiroyuki Tsuchiya
Cancers 2021, 13(17), 4429; https://doi.org/10.3390/cancers13174429
Available online: https://www.mdpi.com/2072-6694/13/17/4429

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office

Conference: RSNA 2023
Organization: The Radiological Society of North America
Date: 26–29 November 2023
Place: McCormick Place, 2301 S. Lake Shore Drive, Chicago, IL 60616 USA
Booth: #1103

The Radiological Society of North America (RSNA) is a non-profit organization. RSNA’s annual meeting provides radiology professionals and industry partners with endless opportunities to learn, connect, exchange ideas, and see the latest technology in action. This year’s theme—Leading through Change—focuses on how radiology professionals can be intentional and proactive while leading teams and organizations through change.

The following MDPI journals will be represented as exhibitors:

• Diagnostics;
• JPM;
• Tomography;
• JCM;
• Osteology;
• Radiation;
• Cancers.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions you may have. For more information about the conference, please visit the following website: https://www.rsna.org/annual-meeting.

September is designated as “Prostate Cancer Awareness Month”, with various global activities that highlight and increase awareness of prostate cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of prostate cancer, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters”
by Piotr Woźnicki, Niklas Westhoff, Thomas Huber, Philipp Riffel, Matthias F. Froelich, Eva Gresser, Jost von Hardenberg, Alexander Mühlberg, Maurice Stephan Michel, Stefan O. Schoenberg et al.
Cancers 2020, 12(7), 1767; https://doi.org/10.3390/cancers12071767
Available online: https://www.mdpi.com/2072-6694/12/7/1767

“Immunotherapy in Prostate Cancer”
by Emily K. Fay and Julie N. Graff
Cancers 2020, 12(7), 1752; https://doi.org/10.3390/cancers12071752
Available online: https://www.mdpi.com/2072-6694/12/7/1752

“The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis”
by Francesco Bonollo, George N. Thalmann, Marianna Kruithof-de Julio and Sofia Karkampouna
Cancers 2020, 12(7), 1887; https://doi.org/10.3390/cancers12071887
Available online: https://www.mdpi.com/2072-6694/12/7/1887

“Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance”
by Maddison Archer, Navneet Dogra and Natasha Kyprianou
Cancers 2020, 12(10), 2984; https://doi.org/10.3390/cancers12102984
Available online: https://www.mdpi.com/2072-6694/12/10/2984

“VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer”
by Daniela Barros-Silva, João Lobo, Catarina Guimarães-Teixeira, Isa Carneiro, Jorge Oliveira, Elena S. Martens-Uzunova, Rui Henrique and Carmen Jerónimo
Cancers 2020, 12(4), 771; https://doi.org/10.3390/cancers12040771
Available online: https://www.mdpi.com/2072-6694/12/4/771

“BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside”
by Stergios Boussios, Elie Rassy, Michele Moschetta, Aruni Ghose, Sola Adeleke, Elisabet Sanchez, Matin Sheriff, Cyrus Chargari and Nicholas Pavlidis
Cancers 2022, 14(16), 3888; https://doi.org/10.3390/cancers14163888
Available online: https://www.mdpi.com/2072-6694/14/16/3888

“Proteomic Analysis of Exosomes for Discovery of Protein Biomarkers for Prostate and Bladder Cancer”
by Yi-Ting Wang, Tujin Shi, Sudhir Srivastava, Jacob Kagan, Tao Liu and Karin D. Rodland
Cancers 2020, 12(9), 2335; https://doi.org/10.3390/cancers12092335
Available online: https://www.mdpi.com/2072-6694/12/9/2335

“Immune Checkpoint Inhibitors in Prostate Cancer”
by Shobi Venkatachalam, Taylor R. McFarland, Neeraj Agarwal and Umang Swami
Cancers 2020, 13(9), 2187; https://doi.org/10.3390/cancers13092187
Available online: https://www.mdpi.com/2072-6694/13/9/2187

“Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer”
by Asta Juzeniene, Vilde Yuli Stenberg, Øyvind Sverre Bruland and Roy Hartvig Larsen
Cancers 2020, 13(4), 779; https://doi.org/10.3390/cancers13040779
Available online: https://www.mdpi.com/2072-6694/13/4/779

“Influence of Intratumor Microbiome on Clinical Outcome and Immune Processes in Prostate Cancer”
by Jiayan Ma, Aditi Gnanasekar, Abby Lee, Wei Tse Li, Martin Haas, Jessica Wang-Rodriguez, Eric Y. Chang, Mahadevan Rajasekaran and Weg M. Ongkeko
Cancers 2020, 12(9), 2524; https://doi.org/10.3390/cancers12092524
Available online: https://www.mdpi.com/2072-6694/12/9/2524

You are welcome to submit relevant papers to the journal Cancers. For more information, contact us at cancers@mdpi.com.

Cancers Editorial Office

MDPI will attend the 13th Member Congress of the Chinese Society of Biochemistry and Molecular Biology and 2023 National Academic Congress. This event will be held from 19 to 22 October 2023 in Hefei, China, and is hosted by the Chinese Society of Biochemistry and Molecular Biology.

This event includes invited reports of the conference, branch (special topic) reports, and posters. The theme of this conference is gene expression and regulation; RNA function and regulation; protein modification and function; metabolic homeostasis and networks; frontier technology and application, etc.

The following MDPI journals will be represented:

• Biomolecules (leading);
• Genes (leading);
• IJMS (leading);
• Cancers;
• Cells;
• Pharmaceutics;
• CIMB;
• Biology;
• Symmetry.

If you plan on attending this conference, please feel free to stop by our booth (#C07) and chat with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://www.csbmb.org.cn/2023/.

We are delighted to share some highly cited papers on hepatocellular carcinoma research that were published in the journal Cancers (ISSN: 2072-6694) in 2021 and 2022. In addition, some Special Issues on this topic are open for submission. The following is a list of articles and Special Issues which we believe will be of interest to you.

“MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma”
by Hyuk Moon and Simon Weonsang Ro
Cancers 2021, 13(12), 3026; https://doi.org/10.3390/cancers13123026
Available online: https://www.mdpi.com/2072-6694/13/12/3026

“Emerging Therapies for Hepatocellular Carcinoma (HCC)”
by Eesha Chakraborty and Devanand Sarkar
Cancers 2022, 14(11), 2798; https://doi.org/10.3390/cancers14112798
Available online: https://www.mdpi.com/2072-6694/14/11/2798

“Tumor-Associated Macrophages in Hepatocellular Carcinoma Pathogenesis, Prognosis and Therapy”
by Konstantinos Arvanitakis, Triantafyllia Koletsa, Ioannis Mitroulis and Georgios Germanidis
Cancers 2022, 14(1), 226; https://doi.org/10.3390/cancers14010226
Available online: https://www.mdpi.com/2072-6694/14/1/226

“The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma”
by Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Anwaar Saeed, Hannah Hildebrand et al.
Cancers 2022, 14(1), 186; https://doi.org/10.3390/cancers14010186
Available online: https://www.mdpi.com/2072-6694/14/1/186

“Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience”
by Maen Abdelrahim, David Victor, Abdullah Esmail, Sudha Kodali, Edward A. Graviss, Duc T. Nguyen, Linda W. Moore, Ashish Saharia, Robert McMillan, Joy N. Fong et al.
Cancers 2022, 14(3), 650; https://doi.org/10.3390/cancers14030650
Available online: https://www.mdpi.com/2072-6694/14/3/650

“Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances”
by Blanca Cucarull, Anna Tutusaus, Patricia Rider, Tania Hernáez-Alsina, Carlos Cuño, Pablo García de Frutos, Anna Colell, Montserrat Marí and Albert Morales
Cancers 2022, 14(3), 621; https://doi.org/10.3390/cancers14030621
Available online: https://www.mdpi.com/2072-6694/14/3/621

We hope this announcement will provide useful information for this field.

September is designated as “Blood Cancer Awareness Month”, with various global activities that highlight and increase awareness of blood cancers for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of blood cancers, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia”
by Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P. González-Rodríguez, Ángel R. Payer, Esther González-García, Alejandro López-Soto and Segundo Gonzalez
Cancers 2021, 13(9), 2112; https://doi.org/10.3390/cancers13092112
Available online: https://www.mdpi.com/2072-6694/13/9/2112

“The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression”
by Almudena García-Ortiz, Yaiza Rodríguez-García, Jessica Encinas, Elena Maroto-Martín, Eva Castellano, Joaquín Teixidó and Joaquín Martínez-López
Cancers 2021, 13(2), 217; https://doi.org/10.3390/cancers13020217
Available online: https://www.mdpi.com/2072-6694/13/2/217

“Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study”
by Evangelos Terpos, Maria Gavriatopoulou, Despina Fotiou, Chara Giatra, Ioannis Asimakopoulos, Maria Dimou, Aimilia D. Sklirou, Ioannis Ntanasis-Stathopoulos, Ismini Darmani, Alexandros Briasoulis et al.
Cancers 2021, 13(17), 4480; https://doi.org/10.3390/cancers13174480
Available online: https://www.mdpi.com/2072-6694/13/17/4480

“Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma”
by Ichiro Hanamura
Cancers 2021, 13(2), 256; https://doi.org/10.3390/cancers13020256
Available online: https://www.mdpi.com/2072-6694/13/2/256

“Janus Kinases in Leukemia”
by Juuli Raivola, Teemu Haikarainen, Bobin George Abraham and Olli Silvennoinen
Cancers 2021, 13(4), 800; https://doi.org/10.3390/cancers13040800
Available online: https://www.mdpi.com/2072-6694/13/4/800

“The Role of Tumor-Associated Macrophages in Hematologic Malignancies”
by Emanuele Cencini, Alberto Fabbri, Anna Sicuranza, Alessandro Gozzetti and Monica Bocchia
Cancers 2021, 13(14), 3597; https://doi.org/10.3390/cancers13143597
Available online: https://www.mdpi.com/2072-6694/13/14/3597

“MicroRNAs: Tiny Regulators of Gene Expression with Pivotal Roles in Normal B-Cell Development and B-Cell Chronic Lymphocytic Leukemia”
by Katerina Katsaraki, Paraskevi Karousi, Pinelopi I. Artemaki, Andreas Scorilas, Vasiliki Pappa, Christos K. Kontos and Sotirios G. Papageorgiou
Cancers 2021, 13(4), 593; https://doi.org/10.3390/cancers13040593
Available online: https://www.mdpi.com/2072-6694/13/4/593

“Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment”
by Susanne Ghandili, Martin Schönlein, Marc Lütgehetmann, Julian Schulze zur Wiesch, Heiko Becher, Carsten Bokemeyer, Marianne Sinn, Katja C. Weisel and Lisa B. Leypoldt
Cancers 2021, 13(15), 3800; https://doi.org/10.3390/cancers13153800
Available online: https://www.mdpi.com/2072-6694/13/15/3800

“Stromal Cells Serve Drug Resistance for Multiple Myeloma via Mitochondrial Transfer: A Study on Primary Myeloma and Stromal Cells”
by Zsolt Matula, Gábor Mikala, Szilvia Lukácsi, János Matkó, Tamás Kovács, Éva Monostori, Ferenc Uher and István Vályi-Nagy
Cancers 2021, 13(14), 3461; https://doi.org/10.3390/cancers13143461
Available online: https://www.mdpi.com/2072-6694/13/14/3461

“FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review”
by Aleksandra Sochacka-Ćwikła, Marcin Mączyński and Andrzej Regiec
Cancers 2022, 14(1), 87; https://doi.org/10.3390/cancers14010087
Available online: https://www.mdpi.com/2072-6694/14/1/87

You are welcome to submit relevant papers to the journal Cancers. For any questions, feel free to contact us.

Cancers Editorial Office

September is designated as “Gynaecological Cancer Awareness Month”, with various global activities that highlight and increase awareness of gynaecological cancers for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of gynaecological cancers, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy”
by Giuseppe Schepisi, Chiara Casadei, Ilaria Toma, Giulia Poti, Maria Laura Iaia, Alberto Farolfi, Vincenza Conteduca, Cristian Lolli, Giorgia Ravaglia, Nicole Brighi et al.
Cancers 2021, 13(4), 840; https://doi.org/10.3390/cancers13040840
Available online: https://www.mdpi.com/2072-6694/13/4/840

“Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review”
by Teska Schuurman, Sanne Zilver, Sanne Samuels, Winnie Schats, Frédéric Amant, Nienke van Trommel and Christianne Lok
Cancers 2021, 13(5), 1008; https://doi.org/10.3390/cancers13051008
Available online: https://www.mdpi.com/2072-6694/13/5/1008

“Small Non-Coding-RNA in Gynecological Malignancies”
by Shailendra Kumar Dhar Dwivedi, Geeta Rao, Anindya Dey, Priyabrata Mukherjee, Jonathan D. Wren and Resham Bhattacharya
Cancers 2021, 13(5), 1085; https://doi.org/10.3390/cancers13051085
Available online: https://www.mdpi.com/2072-6694/13/5/1085

“The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer”
by Rina Masadah, Syahrul Rauf, Muhammad Yogi Pratama, Claudio Tiribelli and Devis Pascut
Cancers 2021, 13(5), 1168; https://doi.org/10.3390/cancers13051168
Available online: https://www.mdpi.com/2072-6694/13/5/1168

“Carbonic Anhydrase IX Promotes Human Cervical Cancer Cell Motility by Regulating PFKFB4 Expression”
by Min-Chieh Hsin, Yi-Hsien Hsieh, Yi-Hsuan Hsiao, Pei-Ni Chen, Po-Hui Wang and Shun-Fa Yang
Cancers 2021, 13(5), 1174; https://doi.org/10.3390/cancers13051174
Available online: https://www.mdpi.com/2072-6694/13/5/1174

“Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data”
by Simona Duranti, Antonella Pietragalla, Gennaro Daniele, Camilla Nero, Francesca Ciccarone, Giovanni Scambia and Domenica Lorusso
Cancers 2021, 13(9), 2089; https://doi.org/10.3390/cancers13092089
Available online: https://www.mdpi.com/2072-6694/13/9/2089

“Molecular and Cellular Mechanisms of Metformin in Cervical Cancer”
by Ya-Hui Chen, Po-Hui Wang, Pei-Ni Chen, Shun-Fa Yang and Yi-Hsuan Hsiao
Cancers 2021, 13(11), 2545; https://doi.org/10.3390/cancers13112545
Available online: https://www.mdpi.com/2072-6694/13/11/2545

“Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment”
by Boštjan Pirš, Erik Škof, Vladimir Smrkolj and Špela Smrkolj
Cancers 2022, 14(3), 631; https://doi.org/10.3390/cancers14030631
Available online: https://www.mdpi.com/2072-6694/14/3/631

“Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?”
by Saikat Mitra, Mashia Subha Lami, Avoy Ghosh, Rajib Das, Trina Ekawati Tallei, Fatimawali, Fahadul Islam, Kuldeep Dhama, M. Yasmin Begum, Afaf Aldahish et al.
Cancers 2022, 14(3), 759; https://doi.org/10.3390/cancers14030759
Available online: https://www.mdpi.com/2072-6694/14/3/759

“Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models”
by Ha-Yeon Shin, Eun-ju Lee, Wookyeom Yang, Hyo Sun Kim, Dawn Chung, Hanbyoul Cho and Jae-Hoon Kim
Cancers 2022, 14(3), 829; https://doi.org/10.3390/cancers14030829
Available online: https://www.mdpi.com/2072-6694/14/3/829

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office

September is designated as “Childhood Cancer Awareness Month”, with various global activities that highlight and increase awareness of childhood cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of childhood cancer, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia”
by Jonathan Lukas Lühmann, Marie Stelter, Marie Wolter, Josephine Kater, Jana Lentes, Anke Katharina Bergmann, Maximilian Schieck, Gudrun Göhring, Anja Möricke, Gunnar Cario et al.
Cancers 2021, 13(17), 4388; https://doi.org/10.3390/cancers13174388
Available online: https://www.mdpi.com/2072-6694/13/17/4388

“Plasticity in Neuroblastoma Cell Identity Defines a Noradrenergic-to-Mesenchymal Transition (NMT)”
by Margot Gautier, Cécile Thirant, Olivier Delattre and Isabelle Janoueix-Lerosey
Cancers 2021, 13(12), 2904; https://doi.org/10.3390/cancers13122904
Available online: https://www.mdpi.com/2072-6694/13/12/2904

“The Microbiome in Childhood Acute Lymphoblastic Leukemia”
by Marina Oldenburg, Nadine Rüchel, Stefan Janssen, Arndt Borkhardt and Katharina L. Gössling
Cancers 2021, 13(19), 4947; https://doi.org/10.3390/cancers13194947
Available online: https://www.mdpi.com/2072-6694/13/19/4947

“Exercise and Childhood Cancer—A Historical Review”
by Javier S. Morales, Pedro L. Valenzuela, Daniel Velázquez-Díaz, Adrián Castillo-García, David Jiménez-Pavón, Alejandro Lucia and Carmen Fiuza-Luces
Cancers 2022, 14(1), 82; https://doi.org/10.3390/cancers14010082
Available online: https://www.mdpi.com/2072-6694/14/1/82

“Management of Nutritional Needs in Pediatric Oncology: A Consensus Statement”
by Francesco Fabozzi, Chiara Maria Trovato, Antonella Diamanti, Angela Mastronuzzi, Marco Zecca, Serena Ilaria Tripodi, Riccardo Masetti, Davide Leardini, Edoardo Muratore, Veronica Barat et al.
Cancers 2022, 14(14), 3378; https://doi.org/10.3390/cancers14143378
Available online: https://www.mdpi.com/2072-6694/14/14/3378

“Childhood Malignant Brain Tumors: Balancing the Bench and Bedside”
by Colin Thorbinson and John-Paul Kilday
Cancers 2021, 13(23), 6099; https://doi.org/10.3390/cancers13236099
Available online: https://www.mdpi.com/2072-6694/13/23/6099

“Neurocognitive Outcomes in Pediatric Patients Following Brain Irradiation”
by Katharina Weusthof, Peggy Lüttich, Sebastian Regnery, Laila König, Denise Bernhardt, Olaf Witt, Klaus Herfarth, Andreas Unterberg, Christine Jungk, Benjamin Farnia et al.
Cancers 2021, 13(14), 3538; https://doi.org/10.3390/cancers13143538
Available online: https://www.mdpi.com/2072-6694/13/14/3538

“The Role of BiP and the IRE1α–XBP1 Axis in Rhabdomyosarcoma Pathology”
by Mahmoud Aghaei, Ahmad Nasimian, Marveh Rahmati, Philip Kawalec, Filip Machaj, Jakub Rosik, Bhavya Bhushan, S. Zahra Bathaie, Negar Azarpira, Marek J. Los et al.
Cancers 2021, 13(19), 4927; https://doi.org/10.3390/cancers13194927
Available online: https://www.mdpi.com/2072-6694/13/19/4927

“Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors”
by Andrew J. Bellantoni and Lars M. Wagner
Cancers 2021, 13(14), 3531; https://doi.org/10.3390/cancers13143531
Available online: https://www.mdpi.com/2072-6694/13/14/3531

“Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth”
by Rameswari Chilamakuri and Saurabh Agarwal
Cancers 2022, 14(4), 1067; https://doi.org/10.3390/cancers14041067
Available online: https://www.mdpi.com/2072-6694/14/4/1067

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office

MDPI is committed to supporting the academic community, nurturing talent and advancing science. Awards are an important part of the research landscape and play a vital role in helping academics gain recognition, especially young researchers as they embark on new research avenues.

In 2022, our journals presented a total number of 394 Awards, including Travel Awards, Young Investigator Awards, Best PhD Thesis Awards, Best Paper Awards, and Outstanding Reviewer Awards, with several winners announced for some of the awards. The total prize sum amounted to just under 580,000 Swiss francs (CHF), or approximately 650,000 US dollars. Overall, more than 720 scholars were awarded.

The majority of the awards were dedicated to young researchers in relatively early stages of their careers. This encompassed 66 of the afore-mentioned Travel Awards, 60 Young Investigator Awards, supporting research projects and conference attendance, as well as 51 Best PhD Thesis Awards. Additionally, 113 Best Paper Awards were given by our journals. The selection committees were entrusted with identifying the most impactful and novel research and review articles published in their journal within a given year.

MDPI will continue its support and recognition for the academic community moving forward, sponsoring new awards across disciplines. To learn more about all the awardees and their research projects in your field of study, please visit the following pages:

To explore more MDPI awards, please click here.

We are pleased to invite you to read the top 10 cited papers in 2020 in Cancers (ISSN: 2072-6694) in the Section "Cancer Drug Development". The paper list is as follows:

1. “Cannabidiol (CBD) as a Promising Anti-Cancer Drug”
by Emily S. Seltzer, Andrea K. Watters, Danny MacKenzie, Jr., Lauren M. Granat and Dong Zhang
Cancers 2020, 12(11), 3203; https://doi.org/10.3390/cancers12113203
Available online: https://www.mdpi.com/2072-6694/12/11/3203

2. “Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines”
by Wei Guo, Hor-Yue Tan, Feiyu Chen, Ning Wang and Yibin Feng
Cancers 2020, 12(2), 404; https://doi.org/10.3390/cancers12020404
Available online: https://www.mdpi.com/2072-6694/12/2/404

3. “Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs”
by Chung-Pu Wu, Sung-Han Hsiao, Yang-Hui Huang, Lang-Cheng Hung, Yi-Jou Yu, Yu-Tzu Chang, Tai-Ho Hung and Yu-Shan Wu
Cancers 2020, 12(1), 195; https://doi.org/10.3390/cancers12010195
Available online: https://www.mdpi.com/2072-6694/12/1/195

4. “Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma”
by Dominika Fassmannová, František Sedlák, Jindřich Sedláček, Ivan Špička and Klára Grantz Šašková
Cancers 2020, 12(5), 1065; https://doi.org/10.3390/cancers12051065
Available online: https://www.mdpi.com/2072-6694/12/5/1065

5. “Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs”
by Chung-Pu Wu, Tai-Ho Hung, Sung-Han Hsiao, Yang-Hui Huang, Lang-Cheng Hung, Yi-Jou Yu, Yu-Tzu Chang, Shun-Ping Wang and Yu-Shan Wu
Cancers 2020, 12(6), 1366; https://doi.org/10.3390/cancers12061366
Available online: https://www.mdpi.com/2072-6694/12/6/1366

6. “Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer”
by Filippos Koinis, Paul Corn, Nila Parikh, Jian Song, Ioulia Vardaki, Ioanna Mourkioti, Sue-Hwa Lin, Christopher Logothetis, Theocharis Panaretakis and Gary Gallick
Cancers 2020, 12(1), 244; https://doi.org/10.3390/cancers12010244
Available online: https://www.mdpi.com/2072-6694/12/1/244

7. “Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1”
by Chenyin Wang, Alexandra Hamacher, Patrick Petzsch, Karl Köhrer, Günter Niegisch, Michèle J. Hoffmann, Wolfgang A. Schulz and Matthias U. Kassack
Cancers 2020, 12(2), 337; https://doi.org/10.3390/cancers12020337
Available online: https://www.mdpi.com/2072-6694/12/2/337

8. “Mambalgin-2 Induces Cell Cycle Arrest and Apoptosis in Glioma Cells via Interaction with ASIC1a”
by Maxim Bychkov, Mikhail Shulepko, Dmitry Osmakov, Yaroslav Andreev, Anastasia Sudarikova, Valeria Vasileva, Marat S. Pavlyukov, Yaroslav A. Latyshev, Alexander A. Potapov, Mikhail Kirpichnikov et al.
Cancers 2020, 12(7), 1837; https://doi.org/10.3390/cancers12071837
Available online: https://www.mdpi.com/2072-6694/12/7/1837

9. “Electroporation-Based Treatments in Urology”
by Aleksander Kiełbik, Wojciech Szlasa, Jolanta Saczko and Julita Kulbacka
Cancers 2020, 12(8), 2208; https://doi.org/10.3390/cancers12082208
Available online: https://www.mdpi.com/2072-6694/12/8/2208

10. “L-Arginine/Nitric Oxide Pathway Is Altered in Colorectal Cancer and Can Be Modulated by Novel Derivatives from Oxicam Class of Non-Steroidal Anti-Inflammatory Drugs”
by Małgorzata Krzystek-Korpacka, Berenika Szczęśniak-Sięga, Izabela Szczuka, Paulina Fortuna, Marek Zawadzki, Agnieszka Kubiak, Magdalena Mierzchała-Pasierb, Mariusz G. Fleszar, Łukasz Lewandowski, Paweł Serek et al.
Cancers 2020, 12(9), 2594; https://doi.org/10.3390/cancers12092594
Available online: https://www.mdpi.com/2072-6694/12/9/2594